Literature DB >> 29248726

Integrative analysis of rewired central metabolism in temozolomide resistant cells.

Selva Rupa C Immanuel1, Avinash D Ghanate2, Dharmeshkumar S Parmar2, Fiona Marriage3, Venkateswarlu Panchagnula2, Philip J Day3, Anu Raghunathan4.   

Abstract

An authenticated U87MG clonal glioblastoma cell line was investigated to identify a sub-population of neurospheroidal (NSP) cells within the main epithelial population (U87MG). The NSP cells sorted using Fluorescence Assisted Cell Sorting (FACS) showed varied morphology, 30% lower growth rates, 40% higher IC50 values for temozolomide drug and could differentiate into the glial cell type (NDx). Metabolite profiling using HR-LCMS identified glucose, glutamine and serine in both populations and tryptophan only in U87MG as growth limiting substrates. Glycine, alanine, glutamate and proline were secreted by U87MG, however proline and glycine were re-utilized in NSP. Exo-metabolite profiling and phenotypic microarrays identified differential metabolism of primary carbon sources glucose and derived pyruvate for U87MG; glutamine and derived glutamate metabolism in NSP. Differential mRNA abundance of AKT1, PTEN, PIK3CA controlling metabolism, drug efflux, nutrient transport and epigenetic control MDM2 are potentially critical in shaping DNA methylation effects of temozolomide. Our study provides a new insight into the combined effect of these factors leading to temozolomide resistance in NSP.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glutamine; Metabolic rewiring; Metabolite profiling; Temozolomide resistance; U87MG; mRNA abundances

Mesh:

Substances:

Year:  2017        PMID: 29248726     DOI: 10.1016/j.bbrc.2017.12.073

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

Review 1.  Employing proteomics to understand the effects of nutritional intervention in cancer treatment.

Authors:  Monica M Schroll; Amanda B Hummon
Journal:  Anal Bioanal Chem       Date:  2018-07-04       Impact factor: 4.478

2.  Integrated genetic and metabolic landscapes predict vulnerabilities of temozolomide resistant glioblastoma cells.

Authors:  Selva Rupa Christinal Immanuel; Avinash D Ghanate; Dharmeshkumar S Parmar; Ritu Yadav; Riya Uthup; Venkateswarlu Panchagnula; Anu Raghunathan
Journal:  NPJ Syst Biol Appl       Date:  2021-01-08

Review 3.  Use of MRI, metabolomic, and genomic biomarkers to identify mechanisms of chemoresistance in glioma.

Authors:  Cathy W Levenson; Thomas J Morgan; Pamela D Twigg; Timothy M Logan; Victor D Schepkin
Journal:  Cancer Drug Resist       Date:  2019-09-19

4.  Peptidylarginine Deiminase Isozyme-Specific PAD2, PAD3 and PAD4 Inhibitors Differentially Modulate Extracellular Vesicle Signatures and Cell Invasion in Two Glioblastoma Multiforme Cell Lines.

Authors:  Pinar Uysal-Onganer; Amy MacLatchy; Rayan Mahmoud; Igor Kraev; Paul R Thompson; Jameel M Inal; Sigrun Lange
Journal:  Int J Mol Sci       Date:  2020-02-22       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.